NRIX · Nurix Therapeutics, Inc.

The thesis

Nurix Therapeutics' case still rests on bexobrutideg, an oral BTK degrader partnered with Roche, and the balance sheet now carries it well past the next trial milestones: the company reported $1.1 billion in cash and marketable securities at 31 August 2026, with a runway into the second half of 2029. The shares closed at $23.67 on 14 October 2026, 14.8% below the 52-week high of $27.79, and the next dataset that can reprice them is the December American Society of Hematology (ASH) meeting.

The Q3 fiscal 2026 report came on 12 October 2026, four days after the 8 October 2026 date the prior note carried. Revenue was $673.1 million, including $653.2 million of Roche license revenue and a $10.0 million Sanofi milestone, and net income was $549.8 million, or $4.73 per diluted share (Nurix 8-K, 12 October 2026). Those totals are one-time accounting for the Roche deal. Collaboration revenue, the recurring line, was $19.9 million.

The narrative is maturing: bexobrutideg is well known, five brokers reset targets on 13 October 2026, and no new clinical data has appeared since the 4 August 2026 first patient in Phase 3 DAYBreak CLL-306. Conviction stays low because the shares are between their 50-day and 200-day moving averages with no dated clinical catalyst before ASH. A close below the 200-day moving average ends the case.

Bullish and bearish views on Nurix Therapeutics, Inc.

The bull case on Nurix Therapeutics, Inc. (NRIX), in brief: Cash covers the pivotal programs. The bear case: Recurring revenue is small.

Bull case

• Cash covers the pivotal programs. Nurix reported $1.1 billion of cash, cash equivalents and marketable securities at 31 August 2026, with a runway into the second half of 2029 (8-K, 12 October 2026). Roche funds 60% of bexobrutideg clinical development costs under the deal announced 8 June 2026.
• Development is widening. Nurix enrolled the first patient in a Phase 1b/2 study of bexobrutideg plus venetoclax in chronic lymphocytic leukemia (CLL) on 7 October 2026. The registrational Phase 3 DAYBreak CLL-306 against pirtobrutinib dosed its first patient on 4 August 2026.
• Partner payments keep arriving. Pfizer paid a $7 million research milestone on 29 September 2026, and Gilead's two-year research extension carries a $10.0 million fee, announced 5 October 2026. Sanofi's $10.0 million milestone was booked in the quarter.
• Analysts remain positive. On 13 October 2026 Baird raised its target to $36 and Oppenheimer raised its to $32. Needham reiterated Buy with a $34 target. MarketBeat showed 13 Buy, 1 Hold and 1 Sell ratings on 1 October 2026.
• Early activity was strong. Nurix reported an 80.9% objective response rate among 47 response-evaluable CLL patients on 9 October 2025. The sample is small and early-stage.

Bear case

• Recurring revenue is small. Collaboration revenue was $19.9 million in the quarter ended 31 August 2026 (8-K, 12 October 2026). The MarketBeat consensus for the report had been $24.35 million of total revenue before the Roche accounting was reflected.
• Two brokers cut targets. RBC lowered its target to $35 and Truist lowered its to $33 on 13 October 2026, both while keeping bullish ratings. The reasons were not stated in the headlines.
• No clinical catalyst is dated before December. The next dataset with weight is ASH, expected ~2026-12. A thin abstract list in ~November would leave the shares without news.

• One asset carries the equity. Phase 3 CLL-306 is a randomized trial of about 620 patients with a multi-year primary readout. Nurix also discontinued development of NX-2127, per the 12 October 2026 release.

Price setup

The last adjusted daily close was $23.67 on 14 October 2026. The 52-week high on this series is $27.79, so the shares sit 14.8% below it. The three-month change is 2.4% and the 14-day relative strength index (RSI) is 50.2, a neutral reading.

MarketBeat put the 50-day moving average at $25.36 and the 200-day at $20.52 on 1 October 2026. The shares are below the first and above the second. The prior note treated $24 as a line the shares had lost; the 14 October 2026 close is $0.33 under it.

Crowding evidence is light. No earnings date is pending, and the only insider activity on record is the planned sales noted above. Retail attention is not measured in the available sources.

Catalysts, next 30 days

• ~2026-11 (est.) — ASH 2026 abstract titles. Shows whether a new bexobrutideg CLL dataset is headed to the December meeting.
• ~2026-12 (est.) — ASH annual meeting. The next place a durability update could appear. It falls outside the 30-day window but is the event the case turns on.
• No earnings report is due. The Q3 fiscal 2026 report is out; the fiscal year ends 30 November 2026, and the next report is expected after the window.

What would change the view

The case breaks if Roche or Nurix discloses a clinical hold, trial termination or enrollment delay in Phase 3 DAYBreak CLL-306, or if ASH abstracts show no new bexobrutideg dataset. On price, a daily close below $20.50, under the 200-day moving average, would end the advance since the spring. A move above the 50-day average near $25 with new clinical data would strengthen the case.

What it trades with

Nurix trades with mid-cap clinical-stage biotech and the broader oncology group, so moves in the biotech index affect the shares independently of company news. Roche's development decisions on BTK degraders bear directly on the lead asset. Competing BTK inhibitors, including pirtobrutinib, set the bar for DAYBreak CLL-306.